• English
    • العربية
  • العربية
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
View Item 
  •   Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Health Sciences
  • Biomedical Sciences
  • View Item
  • Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Health Sciences
  • Biomedical Sciences
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population

    Thumbnail
    View/Open
    Analytic comparison between three highthroughput commercial SARSCoV2.pdf (1.457Mb)
    Date
    2021-06-01
    Author
    Nasrallah, Gheyath K
    Dargham, Soha R
    Shurrab, Farah
    Al-Sadeq, Duaa W
    Al-Jighefee, Hadeel
    Chemaitelly, Hiam
    Al Kanaani, Zaina
    Al Khal, Abdullatif
    Al Kuwari, Einas
    Coyle, Peter
    Jeremijenko, Andrew
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Shaik, Riyazuddin Mohammad
    Rahim, Hanan F Abdul
    Yassine, Hadi M
    Al Kuwari, Mohamed G
    Qotba, Hamda
    Al Romaihi, Hamad Eid
    Tang, Patrick
    Bertollini, Roberto
    Al-Thani, Mohamed H
    Althani, Asmaa A
    Abu-Raddad, Laith J
    ...show more authors ...show less authors
    Metadata
    Show full item record
    Abstract
    Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1-47.8%), 40.6% (95% CI 35.9-45.5%), and 42.4% (95% CI 37.6-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2-95.7%, 89.3-92.8%, and 93.8-97.8%, respectively; Cohen's kappa statistic ranged from 0.86 to 0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively. All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.
    DOI/handle
    http://dx.doi.org/10.1038/s41598-021-91235-x
    http://hdl.handle.net/10576/20550
    Collections
    • Biomedical Research Center Research [‎808‎ items ]
    • Biomedical Sciences [‎833‎ items ]
    • COVID-19 Research [‎849‎ items ]

    entitlement


    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of Digital Hub
      Communities & Collections Publication Date Author Title Subject Type Language Publisher
    This Collection
      Publication Date Author Title Subject Type Language Publisher

    My Account

    Login

    Statistics

    View Usage Statistics

    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Video